Wednesday, November 18, 2026·Focal News

The Boston Focal

Boston's independent voice

Local

Breckenridge Pharmaceutical Recalls One Lot of Propranolol Extended-Release Capsules Nationwide Over Metal Contamination Risk

Breckenridge Pharmaceutical has voluntarily recalled one lot of 60 mg Propranolol Hydrochloride Extended-Release Capsules distributed nationwide between late October and early November 2026, warning the pills may contain metal fragments that could cause internal lacerations. Patients are urged to stop taking the affected medication immediately and contact their doctor.

Breckenridge Pharmaceutical Recalls One Lot of Propranolol Extended-Release Capsules Nationwide Over Metal Contamination Risk

Breckenridge Pharmaceutical, Inc. has issued a voluntary nationwide recall of one lot of Propranolol Hydrochloride Extended-Release Capsules, USP, 60 mg, after the company determined the pills may be contaminated with pieces of metal.

The recall, announced Monday, covers 100-count bottles from lot PK25110035, with the National Drug Code 51991-817-01 and an expiration date of May 2029. The white capsules were manufactured by Adare Pharma and distributed to wholesalers and pharmacies across the country between Oct. 26 and Nov. 4, 2026.

According to the company's announcement, the metal fragments could cause "lacerations of soft tissues in the oral cavity, esophagus, stomach, or intestine." Breckenridge said it has not received any reports of adverse health events linked to the recalled lot.

Patients who were prescribed the medication from the affected lot are advised to stop taking it immediately and contact their doctor. The company also instructed consumers to return any unused portion to the pharmacy where it was obtained. Wholesalers, pharmacies and retailers are being asked to check their inventory for the recalled lot and remove it from shelves.

Propranolol extended-release capsules are beta-blockers that lower blood pressure and heart rate and are commonly prescribed to treat hypertension, according to the Cleveland Clinic.

The recall adds to a string of recent safety actions involving blood pressure medications. Earlier this month, another recall covered Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide tablets because they failed to dissolve properly. Earlier in the fall, thousands of bottles of Chlorthalidone tablets were recalled for the same dissolution problem.

Breckenridge Pharmaceutical did not immediately respond to a request for comment.

For patients, the practical steps are straightforward: check the lot number on the bottle, stop use if it matches PK25110035, and consult a physician about alternative treatment. Community pharmacists can help verify whether a prescription is part of the recalled batch.

More from The Boston Focal